tuneTypical Dose
500-1500 mg
Natural Compound
Curcumin
Diferuloylmethane (from Curcuma longa)
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
4-8 weeks for joint pain and inflammation markers.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Curcumin is a turmeric polyphenol with anti-inflammatory signaling effects and low natural bioavailability. It is used for joint pain and stiffness support and for inflammation biomarker reduction.
Meta-analyses suggest modest reductions in osteoarthritis pain and improvements in function, alongside some reductions in inflammatory biomarkers. Some studies report modest improvements in metabolic syndrome markers. Minority evidence suggests adjunct benefits in depression and certain inflammatory gut conditions. Benefits are more consistent with bioavailability-enhanced formulations than with standard turmeric powders, and the review-level evidence quality is not uniformly strong.
Inhibits COX-2 and LOX enzymes. Downregulates TNF-α, IL-1, and IL-6 pro-inflammatory cytokines. Direct antioxidant and free radical scavenger. Increases BDNF.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduces pain and improves function in osteoarthritis (WOMAC score)
- Lowers systemic inflammation markers (CRP)
Secondary Outcomes
- Mild-to-moderate improvement in depression symptoms
- BDNF upregulation (cognitive support, preliminary)
Safety
Contraindications and Interactions
Contraindications
- Pregnancy (caution)
- Lactation
- Gallstones or bile duct obstruction
- Iron deficiency anemia (curcumin may chelate iron and reduce absorption)
- Anticoagulant or antiplatelet therapy without clinical supervision
Side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Dyspepsia
- Abdominal pain
- Bloating
- Rash
- Contact dermatitis
- Yellow staining of teeth and skin at higher doses
Interactions
- Talinolol (Possible/Moderate) - Curcumin may decrease blood levels of talinolol, but it’s not clear whether this reduces the effectiveness of talinolol.
- Drugs that are CYP1A2 (Possible/Moderate) - Curcumin may inhibit CYP1A2 which could alter the drug levels of medications metabolized by CYP1A2.
- Drugs that are CYP3A4 substrates (Possible/Moderate) - Curcumin may inhibit CYP3A4 and alter blood levels of medications metabolized by CYP3A4.
- Drugs that are CYP2D6 substrates (Possible/Moderate) - Curcumin may inhibit CYP2D6 in the liver.
- Drugs that are BCRP (Possible/Moderate) - Curcumin may inhibit the intestinal drug transporter BCRP, which could increase absorption of medications that are BCRP substrates.
- Sulfasalazine (Possible/Moderate) - Curcumin may increase blood levels of sulfasalazine through enhanced absorption, which could theoretically increase the risk of sulfasalazine side effects.
- Iron (Possible/Moderate) - Human data on the interaction between curcumin and iron supplements is mixed.
- Losartan (Theoretical/Moderate) - Curcumin may increase losartan blood levels, but it’s unclear if this leads to further reductions in blood pressure.
- Drugs that are P-glycoprotein substrates (Theoretical/Moderate) - Curcumin may inhibit p-glycoprotein.
- Anticoagulants and antiplatelets (Possible/Moderate) - Curcumin may potentiate antithrombotic effects and increase bleeding risk (for example warfarin and heparin).
- Chemotherapy agents (Possible/Moderate) - Curcumin may alter efficacy of some chemotherapy agents depending on mechanism and regimen, including possible reduced efficacy in some contexts.
Avoid if
- Pregnancy considerations
- Lactation considerations
- Active gallstone disease
- Bile duct obstruction
- Iron deficiency under treatment
- Anticoagulant or antiplatelet therapy without physician oversight
- People using talinolol
- People using drugs that are cyp1a2
- People using drugs that are cyp3a4 substrates
- People using drugs that are cyp2d6 substrates
- People using drugs that are bcrp
- People using sulfasalazine
- People using iron
Evidence
Study-level References
curcumin-SRC-001Meta-analysis of RCTs
Sourceopen_in_newDaily JW, et al. "Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials." J Med Food. 2016.
Population: Adults with Osteoarthritis
Dose protocol: Source-listed
Key findings: Curcumin extracts provide significant symptom relief in osteoarthritis, comparable to ibuprofen, with fewer gastrointestinal side effects.
Paper content
Curcumin extracts provide significant symptom relief in osteoarthritis, comparable to ibuprofen, with fewer gastrointestinal side effects.
curcumin-SRC-002Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_newHsueh HC, Ho GR, Tzeng SI, Liang KH, Horng YS. Effects of curcumin on serum inflammatory biomarkers in patients with knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2025;25(1):237. doi:10.1186/s12906-025-04951-6. PMID:40615851.
Population: Adults with knee osteoarthritis across 21 randomized studies.
Dose protocol: Oral curcumin and turmeric-extract protocols varied across pooled knee osteoarthritis analyses.
Key findings: Systematic review and meta-analysis found reductions in CRP and TNF-alpha, while several other inflammatory biomarkers remained unchanged.
Notes: Use this study for biomarker framing, not as the main direct pain-and-function anchor.
Paper content
This 2025 systematic review and meta-analysis focused on inflammatory biomarkers in knee osteoarthritis rather than on pain as the primary pooled outcome. Across 21 randomized studies, curcumin significantly lowered CRP and TNF-alpha, while ESR, IL-1beta, IL-6, and PGE-2 did not change significantly. The study is useful for supporting a biologically plausible anti-inflammatory signal in knee osteoarthritis, but it should not be described as a direct umbrella meta-analysis of pain and function outcomes.
curcumin-SRC-003Critical review of systematic reviews and meta-analyses
Sourceopen_in_newChen J, Zhou Q, Yu W, Cao D, Li Y, Chen J, Ye F. A critical review of systematic reviews and meta-analyses of curcumin for knee osteoarthritis. Front Pharmacol. 2026;16:1664319. doi:10.3389/fphar.2025.1664319. PMID:41560742.
Population: Review-level evidence base for curcumin in knee osteoarthritis.
Dose protocol: Review of review-level evidence rather than a single dosing protocol.
Key findings: Critical review concluded that curcumin may help knee osteoarthritis symptoms, but the supporting systematic reviews are methodologically weak and heavily overlapping.
Notes: Important for setting confidence appropriately and avoiding overconfident language.
Paper content
This review does not overturn the signal that curcumin can help some knee osteoarthritis symptoms, but it shows the supporting review literature is methodologically weak and heavily overlapping. That means benefit claims should stay moderate and formulation-specific rather than overly certain.
curcumin-SRC-004Systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_newBahari H, Sharifi M, Nejad Shahrokh Abadi Z, et al. Antihypertensive effects of curcumin/turmeric supplementation in prediabetes and diabetes: a systematic review and meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab. 2026;9(1):e70145. doi:10.1002/edm2.70145. PMID:41388744.
Population: Adults with prediabetes or type 2 diabetes across 15 RCTs (16 treatment arms, n=855).
Dose protocol: Curcumin or turmeric supplementation at various doses across 15 RCTs (n=855) in adults with prediabetes or type 2 diabetes.
Key findings: Meta-analysis found a modest but significant reduction in systolic blood pressure (WMD -2.69 mmHg, P<0.001). Diastolic BP was not significantly affected. SBP reduction was stronger in the hypertensive subgroup (-3.41 mmHg).
Notes: Adds a specific cardiometabolic endpoint beyond OA pain and general CRP reduction. Effect size is small but consistent with anti-inflammatory and vasodilatory mechanisms.
Paper content
This meta-analysis of 15 RCTs (n=855) found that curcumin/turmeric supplementation modestly but significantly reduced systolic blood pressure by about 2.7 mmHg in adults with prediabetes or type 2 diabetes. Diastolic blood pressure was not significantly affected. The SBP reduction was stronger in participants with baseline hypertension (about 3.4 mmHg). The effect size is small but consistent with the vasodilatory and anti-inflammatory mechanisms attributed to curcumin. This adds a specific cardiometabolic endpoint to the curcumin evidence base beyond joint pain and general CRP reduction.
curcumin-SRC-005Randomized, double-blind, placebo-controlled trial
Sourceopen_in_newLopresti AL, Smith SJ, Jackson-Michel S, Fairchild T. An Investigation into the Effects of a Curcumin Extract (Curcugen®) on Osteoarthritis Pain of the Knee: A Randomised, Double-Blind, Placebo-Controlled Study. Nutrients. 2021;14(1):41. doi:10.3390/nu14010041. PMID:35010916.
Population: Adults with knee osteoarthritis.
Dose protocol: Curcugen 500 mg twice daily for 8 weeks in adults with knee osteoarthritis
Key findings: Improved KOOS pain, numeric pain ratings, timed up-and-go, and 6-minute walk outcomes versus placebo.
Notes: Good direct RCT anchor for symptom and function benefit, but still formulation specific.
Paper content
This 8-week randomized, double-blind, placebo-controlled trial tested 500 mg of Curcugen twice daily in 101 adults with knee osteoarthritis. Compared with placebo, curcumin significantly improved KOOS pain, numeric knee pain ratings, timed up-and-go performance, 6-minute walk distance, and the Japanese Orthopaedic Association total score. It did not improve every physical-performance endpoint, which fits the broader theme that curcumin benefit is real but formulation specific and not uniform across measures.